DXCM DexCom, Inc. Stock Quote

DXCM [NASD]

Healthcare | Diagnostics & Research | USA

Index	S&P 500	P/E	153.20	EPS (ttm)	2.42	Insider Own	0.80%	Shs Outstand	95.80M	Perf Week	5.12%
Market Cap	35.33B	Forward P/E	113.71	EPS next Y	3.26	Insider Trans	-23.74%	Shs Float	95.57M	Perf Month	6.10%
Income	231.10M	PEG	5.69	EPS next Q	0.92	Inst Own	98.90%	Short Float	3.61%	Perf Quarter	-4.57%
Sales	1.82B	P/S	19.40	EPS this Y	175.80%	Inst Trans	1.74%	Short Ratio	2.89	Perf Half Y	-11.88%
Book/sh	15.65	P/B	23.65	EPS next Y	5.17%	ROA	7.60%	Target Price	460.22	Perf Year	57.10%
Cash/sh	27.28	P/C	13.57	EPS next 5Y	26.90%	ROE	19.80%	52W Range	182.07 - 456.23	Perf YTD	0.11%
Dividend	-	P/FCF	133.62	EPS past 5Y	41.50%	ROI	7.10%	52W High	-18.87%	Beta	0.79
Dividend %	-	Quick Ratio	6.00	Sales past 5Y	41.60%	Gross Margin	66.30%	52W Low	103.28%	ATR	12.32
Employees	3900	Current Ratio	6.40	Sales Q/Q	26.40%	Oper. Margin	16.00%	RSI (14)	55.60	Volatility	2.72% 3.44%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	46.60%	Profit Margin	12.70%	Rel Volume	0.35	Prev Close	367.50
Shortable	Yes	LT Debt/Eq	1.13	Earnings	Feb 11 AMC	Payout	0.00%	Avg Volume	1.20M	Price	370.12
Recom	1.60	SMA20	1.63%	SMA50	6.26%	SMA200	-2.42%	Volume	424,267	Change	0.71%

Jan-06-21

Upgrade

UBS

Neutral → Buy

$410 → $445

Oct-02-20

Downgrade

Wells Fargo

Equal Weight → Underweight

$420 → $350

May-27-20

Reiterated

Piper Sandler

Overweight

$375 → $450

May-14-20

Initiated

Wells Fargo

Equal Weight

$420

Mar-05-20

Initiated

Citigroup

Buy

$330

Nov-07-19

Upgrade

Guggenheim

Neutral → Buy

Nov-07-19

Reiterated

Canaccord Genuity

Buy

$185 → $195

Oct-23-19

Initiated

Stifel

Buy

Nov-28-18

Initiated

UBS

Neutral

$135

Oct-19-18

Upgrade

Goldman

Sell → Neutral

Sep-12-18

Upgrade

Northland Capital

Under Perform → Market Perform

Aug-02-18

Reiterated

Canaccord Genuity

Buy

$105 → $125

Jul-02-18

Upgrade

Raymond James

Mkt Perform → Outperform

Jun-08-18

Upgrade

JP Morgan

Neutral → Overweight

May-11-18

Initiated

BofA/Merrill

Buy

$100

May-03-18

Reiterated

Canaccord Genuity

Buy

$81 → $85

Apr-04-18

Initiated

Guggenheim

Neutral

Apr-04-18

Initiated

Goldman

Sell

$57

Mar-23-18

Upgrade

Robert W. Baird

Neutral → Outperform

Jan-04-18

Downgrade

Northland Capital

Market Perform → Under Perform

Jan-19-21 08:30AM	Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time Business Wire
06:08AM	Abbott vs Dexcom: Which Strong Buy Stock Could Deliver Higher Returns in 2021? TipRanks
Jan-18-21 01:55AM	Is DexCom (NASDAQ:DXCM) A Risky Investment? Simply Wall St.
Jan-13-21 09:32AM	DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues Zacks
Jan-12-21 01:27PM	Teladoc (TDOC) and Dexcom Offer New Solutions for Diabetes Zacks
06:33AM	2 Healthcare Stocks That Crushed the Market Last Year -- And Still Have Room to Grow Motley Fool
Jan-11-21 12:46PM	DexCom 4th-Period Revenue Estimate Beats Analyst Expectations TheStreet.com
07:30AM	Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook Business Wire
Jan-08-21 05:45PM	DexCom (DXCM) Gains But Lags Market: What You Should Know Zacks
Jan-07-21 01:18PM	12 Best Telemedicine Stocks to Buy Now Insider Monkey
Jan-05-21 08:30AM	Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference Business Wire
07:08AM	3 Recession-Proof Healthcare Stocks to Buy for 2021 Motley Fool
06:36AM	3 Nasdaq 100 Stocks That Can Make You a Boatload of Money in 2021 Motley Fool
Jan-03-21 08:19PM	14 Best Internet of Things Stocks To Buy Now Insider Monkey
Dec-30-20 06:06AM	4 High-Growth Trends You'll Want to Invest in for 2021 Motley Fool
Dec-24-20 05:45PM	DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know Zacks
Dec-18-20 05:45PM	DexCom (DXCM) Gains As Market Dips: What You Should Know Zacks
Dec-17-20 07:10AM	Up 60% In 2020, Here's Why DexCom Is Just Getting Started Motley Fool
Dec-10-20 09:10AM	DexCom Shares Could Weaken Still Further in the Months Ahead TheStreet.com
Dec-09-20 06:12AM	DexCom Has a Lot to Prove in 2021 Motley Fool
Dec-08-20 06:08AM	Diabetes Awareness Month review: patients in Quebec and Canada have legitimate expectations CNW Group
Dec-07-20 10:23AM	Is DXCM A Good Stock To Buy Now? Insider Monkey
Dec-06-20 06:24AM	3 Top Healthcare Stocks to Buy Right Now Motley Fool
Dec-04-20 12:51AM	Returns On Capital - An Important Metric For DexCom (NASDAQ:DXCM) Simply Wall St.
Dec-01-20 02:40AM	Medtronic or Dexcom: Which Medical Device Stock Is Poised To Deliver Higher Gains? TipRanks
Nov-30-20 01:31PM	Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom Zacks
Nov-28-20 06:50AM	3 Highest-Growth Stocks in the Market Today Motley Fool
Nov-27-20 09:07AM	IoMT Meets New Healthcare Needs: 3 MedTech Trends to Watch Zacks
Nov-25-20 10:40AM	DexCom Could Work Itself Lower in the Weeks Ahead TheStreet.com
Nov-19-20 07:04AM	Could DexCom Be a Millionaire-Maker Stock? Motley Fool
Nov-18-20 06:36AM	These 3 Medical Device Stocks Leave Biotech in the Dust Motley Fool
Nov-17-20 08:39AM	Better Buy: Abbott Laboratories vs. DexCom Motley Fool
Nov-14-20 09:08AM	Forget Snowflake! Buy This Ultra-High-Growth Stock Motley Fool
08:08AM	Forget Apple! Buy These 2 High-Growth Stocks Instead Motley Fool
Nov-12-20 08:45AM	Dexcom Announces Upcoming Virtual Conference Presentations Business Wire
06:53AM	5 Top Healthcare Stocks to Buy in November Motley Fool
Nov-10-20 10:00AM	Why DexCom Stock Crumbled in October Motley Fool
Nov-07-20 05:06AM	Why Is No One Talking About DexCom Stock? Motley Fool
Nov-04-20 04:39PM	Stock Upgrades: Dexcom Shows Rising Relative Strength Investor's Business Daily
Nov-03-20 10:18AM	Dexcom to Host Investor Day on December 9, 2020 Business Wire +6.34%
Oct-29-20 11:10AM	Go Slow on Any DexCom Purchases for Now TheStreet.com
08:10AM	DexCom, Inc. Just Recorded A 58% EPS Beat: Here's What Analysts Are Forecasting Next Simply Wall St.
Oct-28-20 10:30AM	DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates Zacks -8.28%
06:02AM	How DexCom Trounced Wall Street Estimates in Q3 Motley Fool
03:31AM	Dexcom Drops 9% As Revenue Beat Fails To Impress Investors SmarterAnalyst
Oct-27-20 09:01PM	Dexcom Inc (DXCM) Q3 2020 Earnings Call Transcript Motley Fool -8.94%
05:35PM	DexCom (DXCM) Q3 Earnings and Revenues Top Estimates Zacks
04:34PM	Recap: DexCom Q3 Earnings Benzinga
04:03PM	Dexcom Reports Third Quarter 2020 Financial Results Business Wire
08:24AM	The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga
07:58AM	Dow Jones Futures Signal Stock Market Rally Boost Amid Earnings Flood, AMD-Xilinx Deal Investor's Business Daily
06:25AM	Dow Jones Futures: Stock Market Rally Struggles As Coronavirus Cases Soar; Dexcom Leads Key Movers Late Investor's Business Daily
05:51AM	4 Smart Stocks That'll Make Robinhood Investors Rich Motley Fool
Oct-26-20 04:42PM	Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue Business Wire
11:53AM	Dexcom Gains Ahead Of Earnings Investor's Business Daily Video
Oct-24-20 07:22AM	Why I Just Bought These 2 Under-the-Radar Stocks Motley Fool
Oct-21-20 05:45PM	DexCom (DXCM) Dips More Than Broader Markets: What You Should Know Zacks
12:06PM	Were Hedge Funds Right About DexCom, Inc. (DXCM)? Insider Monkey
07:35AM	DexCom (DXCM) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-20-20 12:31PM	DexCom (DXCM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
12:10PM	Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report? Zacks
11:32AM	2 Unstoppable Stocks That Are Better Buys Than Apple Motley Fool
Oct-14-20 05:45PM	DexCom (DXCM) Dips More Than Broader Markets: What You Should Know Zacks
Oct-13-20 08:30AM	Dexcom Appoints Kyle Malady to Board of Directors Business Wire
05:51AM	3 Must-Own Growth Stocks for Robinhood Investors Motley Fool
Oct-10-20 09:33AM	A Closer Look At DexCom, Inc.'s (NASDAQ:DXCM) Impressive ROE Simply Wall St.
Oct-08-20 05:45PM	DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know Zacks
Oct-07-20 04:18PM	Masimo Gives Its First 2020 Guidance After Covid-19 'Uncertainties'; MASI Stock Rises Investor's Business Daily +5.05%
06:30AM	Lilly and Dexcom team up on new program to help improve diabetes management PR Newswire
Oct-02-20 12:23PM	Why DexCom Stock Is Slipping Today Motley Fool -7.08%
Oct-01-20 05:45PM	DexCom (DXCM) Gains But Lags Market: What You Should Know Zacks
08:30AM	Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time. Business Wire
Sep-29-20 04:41AM	DexCom Publishes Study Showcasing The Cost Effectiveness Of The DexCom G6 Continuous Glucose Monitoring System PR Newswire
Sep-28-20 04:20PM	Abbott Labs Gets European Approval For Newest Version Of Its Glucose Monitoring System Investor's Business Daily
Sep-24-20 02:49PM	Dexcom and University of Virginia to Advance Diabetes Research Together Motley Fool
08:30AM	Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research Business Wire
06:23AM	3 Solid Stocks to Get You Through a Market Crash Motley Fool
Sep-22-20 08:51AM	4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis Zacks
08:30AM	Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States Business Wire
Sep-18-20 05:45PM	DexCom (DXCM) Gains As Market Dips: What You Should Know Zacks
09:07AM	DexCom Introduces Registry to Monitor Outcomes of G6 System Zacks
08:00AM	Do You Own The 10 Most Expensive Stocks Right Now? Investor's Business Daily
Sep-17-20 07:00AM	If You Invested $5,000 in Dexcom During the Coronavirus Market Crash, This Is How Much Money You'd Have Now Motley Fool
Sep-16-20 08:30AM	Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic Business Wire
Sep-11-20 05:45PM	DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know Zacks
Sep-10-20 05:51AM	3 Stocks for Robinhood Investors to Buy During a Stock Market Crash Motley Fool
Sep-04-20 12:08PM	Why DexCom, Livongo Health, and Teladoc Health Stocks Are Tumbling Today Motley Fool
09:36AM	Shareholders Are Raving About How The DexCom (NASDAQ:DXCM) Share Price Increased 479% Simply Wall St.
09:11AM	2 Healthcare Stocks You Should Buy, According to Wall Street Motley Fool
08:45AM	Dexcom Announces Upcoming Virtual Conference Presentations Business Wire
07:00AM	Top Mutual Fund Manager Likens Amazon To The 'Evil Empire' Investor's Business Daily
Sep-02-20 03:35PM	Dow, S&P 500 Spearhead Gains; These Growth Stocks Still Lead Investor's Business Daily +6.04%
03:15PM	Why DexCom Stock Jumped Today Motley Fool
10:57AM	Dexcom Springs To Life After Flat Action Investor's Business Daily Video
Aug-31-20 02:13PM	DexCom, Inc. (DXCM): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Aug-27-20 11:31AM	DexCom (DXCM) Down 0.3% Since Last Earnings Report: Can It Rebound? Zacks
07:24AM	These 5 Stocks Are The Biggest S&P 500 Healthcare Winners of 2020 Motley Fool
Aug-26-20 03:28PM	Top Stocks for September 2020 Investopedia
01:27PM	Nevro Earns Relative Strength Rating Upgrade; Hits Key Benchmark Investor's Business Daily
Aug-24-20 01:12PM	Top Health Care Stocks for September 2020 Investopedia

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; a collaboration with Companion Medical, Inc.; and a development and commercialization agreement with Tandem Diabetes Care, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAYER KEVIN R	Chairman, CEO & President	Jan 13	Sale	353.55	7,073	2,500,653	144,402	Jan 14 05:06 PM
SAYER KEVIN R	Chairman, CEO & President	Jan 12	Sale	362.09	39,949	14,465,252	151,475	Jan 14 05:06 PM
AUGUSTINOS NICHOLAS	Director	Jan 06	Sale	375.00	625	234,375	11,967	Jan 07 04:40 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Jan 04	Sale	366.06	11,025	4,035,812	21,524	Jan 06 05:10 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Dec 28	Sale	355.39	500	177,695	19,078	Dec 29 08:58 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Dec 23	Sale	359.85	1,079	388,276	59,781	Dec 28 05:43 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Dec 23	Sale	359.92	1,110	399,516	9,983	Dec 28 05:43 PM
AUGUSTINOS NICHOLAS	Director	Dec 16	Sale	354.55	1,250	443,183	12,592	Dec 18 07:53 PM
Heller Bridgette P	Director	Dec 15	Sale	356.65	375	133,744	3,448	Dec 17 05:12 PM
SAYER KEVIN R	Chairman, CEO & President	Dec 01	Sale	322.18	13,233	4,263,358	115,514	Dec 03 05:11 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Dec 01	Sale	325.00	6,154	2,000,050	19,578	Dec 03 05:11 PM
Sylvain Jereme M	SVP, Finance & CAO	Nov 24	Sale	320.37	600	192,222	11,300	Nov 25 04:50 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Nov 23	Sale	318.99	1,079	344,190	60,860	Nov 25 04:50 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Nov 23	Sale	318.99	1,110	354,079	11,093	Nov 25 04:50 PM
FOLETTA MARK G	Director	Nov 16	Sale	341.32	1,000	341,320	13,202	Nov 18 06:57 PM
Sylvain Jereme M	SVP, Finance & CAO	Nov 10	Sale	336.22	632	212,491	11,900	Nov 12 05:39 PM
SAYER KEVIN R	President, CEO and Chairman	Oct 29	Sale	340.14	13,830	4,704,197	128,747	Oct 30 05:01 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Oct 23	Sale	403.18	1,079	435,030	61,939	Oct 27 06:20 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Oct 23	Sale	403.10	1,110	447,444	12,203	Oct 27 06:19 PM
FOLETTA MARK G	Director	Oct 15	Sale	396.82	1,000	396,819	14,202	Oct 19 04:30 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Oct 01	Sale	420.00	200	84,000	63,018	Oct 02 06:08 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Sep 30	Sale	410.32	2,000	820,637	63,218	Oct 02 06:08 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Sep 25	Sale	400.07	2,000	800,137	65,218	Sep 28 05:35 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Sep 24	Sale	380.95	1,530	582,861	0	Sep 28 05:35 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Sep 23	Sale	395.11	1,079	426,324	67,218	Sep 24 04:30 PM
AUGUSTINOS NICHOLAS	Director	Sep 16	Sale	399.78	1,875	749,596	13,842	Sep 18 04:57 PM
Balo Andrew K	*	Sep 15	Sale	397.35	5,256	2,088,490	35,567	Sep 16 04:44 PM
ALTMAN STEVEN R	Director	Sep 15	Sale	393.92	30,000	11,817,600	12,980	Sep 16 07:36 PM
FOLETTA MARK G	Director	Sep 14	Sale	394.14	1,000	394,136	15,202	Sep 16 04:44 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Sep 10	Sale	400.62	2,102	842,104	17,753	Sep 11 06:59 PM
Blackford Quentin S.	Chief Operating Officer & CFO	Sep 10	Sale	400.59	12,193	4,884,343	44,124	Sep 11 06:57 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Sep 09	Sale	398.30	2,444	973,450	25,732	Sep 11 06:58 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Sep 09	Sale	398.30	4,580	1,824,223	68,297	Sep 11 06:58 PM
SAYER KEVIN R	President, CEO and Chairman	Sep 09	Sale	398.30	9,965	3,969,079	142,577	Sep 11 06:59 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Sep 09	Sale	398.30	2,226	886,620	19,855	Sep 11 06:59 PM
Sylvain Jereme M	SVP, Finance & CAO	Sep 09	Sale	398.30	289	115,109	12,532	Sep 11 06:59 PM
Balo Andrew K	*	Sep 09	Sale	398.30	4,580	1,824,223	40,823	Sep 11 06:57 PM
Blackford Quentin S.	Chief Operating Officer & CFO	Sep 09	Sale	398.30	12,886	5,132,520	56,317	Sep 11 06:57 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Sep 09	Sale	398.30	4,699	1,871,621	46,812	Sep 11 06:58 PM
Leach Jacob Steven	EVP Chief Technology Officer	Sep 09	Sale	398.30	3,860	1,537,446	103,548	Sep 11 06:58 PM
Abbey Donald	EVP Quality and Regulatory Aff	Sep 09	Sale	394.43	9,739	3,841,392	50,202	Sep 11 06:57 PM
Abbey Donald	EVP Quality and Regulatory Aff	Aug 24	Sale	424.66	9,766	4,147,227	59,941	Aug 26 07:03 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Aug 24	Sale	427.22	1,530	653,642	1,530	Aug 26 07:03 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Aug 24	Sale	427.24	1,531	654,107	72,877	Aug 26 07:04 PM
Sylvain Jereme M	SVP, Finance & CAO	Aug 24	Sale	427.41	600	256,446	12,817	Aug 26 07:04 PM
ALTMAN STEVEN R	Director	Aug 10	Sale	435.05	2,000	870,093	42,980	Aug 12 05:11 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Aug 10	Sale	439.31	500	219,655	28,176	Aug 12 05:11 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Aug 10	Sale	439.31	400	175,724	22,041	Aug 12 05:11 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Jul 23	Sale	427.31	1,531	654,213	74,408	Jul 27 05:53 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Jul 23	Sale	427.29	1,531	654,188	3,060	Jul 27 05:53 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Jul 10	Sale	439.33	400	175,732	22,441	Jul 14 04:27 PM
ALTMAN STEVEN R	Director	Jul 10	Sale	437.50	2,000	874,993	44,980	Jul 14 04:27 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Jul 09	Sale	435.80	500	217,900	28,676	Jul 10 05:13 PM
SAYER KEVIN R	President, CEO and Chairman	Jul 06	Sale	420.94	6,000	2,525,662	152,542	Jul 08 07:01 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Jun 23	Sale	409.41	1,531	626,807	4,591	Jun 25 06:45 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Jun 23	Sale	409.37	1,531	626,750	75,939	Jun 25 06:45 PM
AUGUSTINOS NICHOLAS	Director	Jun 15	Sale	366.65	1,875	687,463	15,717	Jun 17 06:01 PM
Balo Andrew K	*	Jun 15	Sale	366.47	6,522	2,390,096	45,376	Jun 17 06:01 PM
Leach Jacob Steven	EVP Chief Technology Officer	Jun 11	Sale	376.76	19,129	7,207,029	107,369	Jun 15 06:00 PM
ALTMAN STEVEN R	Director	Jun 10	Sale	385.71	2,000	771,413	46,980	Jun 12 06:54 PM
KAHN BARBARA	Director	Jun 10	Sale	380.71	7,000	2,665,001	6,879	Jun 12 06:54 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Jun 10	Sale	385.22	400	154,088	22,841	Jun 12 06:54 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Jun 09	Sale	375.36	500	187,680	29,176	Jun 10 05:50 PM
SAYER KEVIN R	President, CEO and Chairman	Jun 01	Sale	376.57	6,000	2,259,400	158,542	Jun 02 04:43 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	May 26	Sale	408.49	1,474	602,114	23,241	May 28 06:47 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	May 22	Sale	396.74	1,531	607,409	77,470	May 27 06:06 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	May 22	Sale	396.74	1,531	607,409	6,122	May 27 05:56 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	May 11	Sale	404.05	400	161,620	24,715	May 13 06:30 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	May 11	Sale	404.05	500	202,025	29,676	May 13 06:16 PM
SAYER KEVIN R	President, CEO and Chairman	May 04	Sale	344.63	6,000	2,067,761	164,542	May 06 08:34 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Apr 23	Sale	318.57	1,530	487,412	7,653	Apr 27 05:00 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Apr 23	Sale	318.57	1,531	487,731	79,001	Apr 27 04:51 PM
Balo Andrew K	*	Apr 15	Sale	283.39	6,690	1,895,895	51,898	Apr 17 06:04 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Apr 13	Sale	279.88	400	111,952	25,394	Apr 15 05:18 PM
Murphy Patrick Michael	EVP, Chief Legal Officer	Apr 09	Sale	259.95	500	129,975	30,176	Apr 13 06:44 PM
SAYER KEVIN R	President, CEO and Chairman	Apr 07	Sale	262.81	6,000	1,576,839	170,542	Apr 08 06:10 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Mar 30	Sale	271.79	1,214	329,950	25,794	Apr 01 05:37 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Mar 23	Sale	209.23	1,531	320,335	80,532	Mar 25 06:22 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Mar 23	Sale	209.27	1,531	320,396	9,183	Mar 25 06:10 PM
Blackford Quentin S.	Chief Operating Officer & CFO	Mar 12	Sale	233.55	6,353	1,483,724	69,203	Mar 13 09:17 PM
DOUBLEDAY RICHARD	EVP Chief Commercial Officer	Mar 11	Sale	264.74	8,303	2,198,160	52,005	Mar 13 09:36 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Mar 11	Sale	264.70	3,387	896,528	27,008	Mar 13 09:20 PM
SAYER KEVIN R	President, CEO and Chairman	Mar 11	Sale	264.82	20,374	5,395,432	190,016	Mar 13 09:17 PM
Blackford Quentin S.	Chief Operating Officer & CFO	Mar 11	Sale	264.78	6,208	1,643,725	75,556	Mar 13 09:17 PM
MOY JEFFREY	EVP Operations	Mar 11	Sale	264.76	6,203	1,642,289	31,397	Mar 13 09:17 PM
Sylvain Jereme M	SVP, Finance & CAO	Mar 11	Sale	264.83	613	162,340	13,417	Mar 13 09:17 PM
Leach Jacob Steven	EVP Chief Technology Officer	Mar 11	Sale	264.69	6,909	1,828,756	127,498	Mar 13 09:17 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Mar 11	Sale	264.82	8,049	2,131,534	84,313	Mar 13 09:11 PM
Murphy Patrick Michael	*	Mar 11	Sale	264.77	4,082	1,080,794	30,676	Mar 13 09:07 PM
Balo Andrew K	*	Mar 11	Sale	264.82	8,161	2,161,231	58,588	Mar 13 09:29 PM
Abbey Donald	EVP Quality and Regulatory Aff	Mar 11	Sale	264.68	8,050	2,130,657	69,707	Mar 13 09:28 PM
ACE HEATHER S	SVP Human Resources	Mar 11	Sale	264.69	6,207	1,642,902	38,584	Mar 13 09:28 PM
Blackford Quentin S.	Chief Operating Officer & CFO	Mar 09	Sale	261.00	891	232,551	81,764	Mar 10 08:19 PM
SAYER KEVIN R	President, CEO and Chairman	Mar 09	Sale	269.02	6,000	1,614,099	210,390	Mar 10 07:34 PM
ACE HEATHER S	SVP Human Resources	Mar 09	Sale	269.75	7,885	2,126,955	44,791	Mar 10 08:56 PM
Selvaraj Shelly Ramasamy	SVP Information Technology	Mar 09	Sale	261.00	439	114,579	30,395	Mar 10 08:29 PM
Murphy Patrick Michael	*	Mar 09	Sale	261.00	500	130,500	34,758	Mar 10 06:49 PM
Pacelli Steven Robert	EVP Strategy and Corporate Dev	Mar 05	Option Exercise	9.80	8,927	87,485	83,551	Mar 09 05:11 PM
FOLETTA MARK G	Director	Mar 03	Sale	277.08	1,000	277,079	13,147	Mar 04 06:42 PM
MOY JEFFREY	EVP Operations	Mar 02	Sale	278.10	362	100,672	25,032	Mar 03 08:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience